Purpose: To define prevalence and natural history of patients with hypertrophic cardiomyopathy (HCM) and apical aneurysms (AA). Methods: A single center-cohort consisting of 423 patients (49.3±17.2 years, 66.2% male) was followed up for a median of 84 months (range 6 to 480 months). A left ventricular (LV) AA was defined as a discrete, thin-walled dyskinetic or akinetic apex with a relatively wide communication to the LV cavity recognised both by means of echocardiography and magnetic resonance imaging, Figure 1 . Cumulative SD event rates through follow up were estimated by Kaplan-Meier method and differences were assessed by log rank test. Results: AA were recognized in 11 out of 423 patients in our cohort (2.6%). Nine out of 11 patients (81.8%) with AA presented also with midventricular obstruction (MVO), with apical aneurysm formation identified in more than one fourth of patients with MVO (26.5%). During follow up, 4 out of 11 patients with an AA (36.4%) experienced progression to end stage HCM (burnt out) or death due to heart failure (HF), with the survival rates from HF and associated death being significantly lower in the aneurysm group [ Conclusions: AA is a distinct phenotypic characteristic of HCM associated with an unfavorable prognosis in terms of progression to end stage HCM (burnt out) or death due to HF. Additionally, there is a clear connection between MVO and apical aneurysms.
Backgrounds and purpose: Peak oxygen consumption (VO2) measured by cardiopulmonary exercise testing (CPET) is considered to be a strong predictor of cardiac events. Myocardial contractile reserve, the left ventricular (LV) response to dobutamine stress testing, also provides useful prognostic information. The aim of this study was to investigate the relation between myocardial contractile reserve and exercise capacity in prognosis of non-ischemic dilated cardiomyopathy (NIDCM).
Kaplan-Meier survival curves
Methods: Fifty-two ambulatory patients with NIDCM were enrolled. All subjects underwent CPET as well as to cardiac catheterization for measurement of the maximal first derivative of left ventricular pressure (LV dP/dt max). We calculated the percentage increase in LV dP/dt max ( LV dP/dt max) under the dobutamine stress as an index of myocardial contractile reserve. All patients were followed up for an average of 1040 days. Results: The mean age, LV ejection fraction, and plasma brain natriuretic peptide level were 52 [yrs], 33 [%] , and 178 [pg/mL]. LV dP/dt max (10γ) was significantly correlated with peak VO2 (r=0.38, p=0.006). In the peak VO2<18 group, the rate of cardiac events was significantly lower than the peak VO2≥18 group (p=0.021). On the other hand, in the LV dP/dt max<60% group, cardiac events were significantly higher than in the LV dP/dt max≥60% group. Peak VO2<18 (Hazard Ratio: 3.18, p=0.029) and LV dP/dtmax<60% (Hazard Ratio: 3.25, p=0.026) were comparable predictors of cardiac events. Conclusions: Evaluating myocardial contractile reserve in dobutamine stress testing and peak VO2 in CPET might be complementary approaches to predict a prognosis of NIDCM.
P2963 | BEDSIDE
Prevalence and outcome of cardiogenic shock in patients with tako-tsubo cardiomyopathy Purpose: Tako-tsubo cardiomyopathy (TTC) is regarded a benign disease since left ventricular (LV) function returns to normal within a short period of time. However, severe complications have been described in a limited number of patients (pts). This study evaluated the frequency and outcome of cardiogenic shock in a large TTC registry. Methods: From 37 heart centres, 324 pts (296 f, 28 m, age 68±12) were included in the registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte according to the following criteria: 1) acute chest symptoms, 2) ischemic ECG changes, 3) reversible LV akinesia not corresponding to a single coronary artery territory, 4) absence of coronary artery stenoses. Complete data on complications were available in the last 209 registry pts. Results: Complications developed in 108/209 pts (52%) within 2.6±2.9 days (median 1 [IQR 1-3] days) after symptom onset; 51 of these pts (24%) experienced >1 and 23 (11%) >2 complications. Most complications (77%) occurred within 3 days after symptom onset, however, 23% developed later (from day 4 to 56). Fourteen of 209 pts (7%) experienced cardiogenic shock which developed on the day of admission in 11 pts (79%) and from day 2 to day 4 after admission in 3 pts (21%). Seven of these patients (50%) were also in pulmonary oedema. The ECG on admission showed a higher heart rate (92±24 vs. 76±17 beats per minute, p<0.001) and more Q waves in pts with cardiogenic shock (54% vs. 27%, p=0.043). Cardiac markers were significantly higher (creatine kinase 4.3±5.7 vs. 1.8±3.8 [p<0.05] and troponin 62.1±109 vs. 10.7±11.9 [p<0.001] times the upper limit of normal), and ejection fraction was lower (38±9 vs. 51±15%, p<0.005). Intraaortic balloon pumping was applied in 2/14 pts, and catecholamines were administered in 8 pts. Four of 14 TTC pts with cardiogenic shock (29%) died, 2 from multiorgan failure and 1 pt each from refractory cardiogenic shock and LV rupture. In the latter pt ST-segment elevation persisted for 3 days when myocardial perforation occurred. Conclusion: Cardiogenic shock occurs in 7% of pts with TTC. The prevalence of cardiogenic shock is similar to findings in reperfused myocardial infarction (5-10%). However, the mortality of cardiogenic shock in TTC pts appears to be lower (29%) than reported in reperfused patients with ST-elevation myocardial infarction (42-62%). This may be due to the early spontaneous reversibility of LV dysfunction in TTC. Purpose: Cardiac fibrosis is the most important histological characteristics of viral cardiomyopathy and is associated with poor prognosis and therapeutic interventions. BMP7 is a member of TGF-β superfamily and was reported to counteract the effects of TGF-β1. This study was designed to evaluate whether BMP7 administration could reduce fibrosis induced by CVB3 infection and its potential mechanism. Methods: Viral myocarditis mice model was made and BMP7 was administrated to infected mice. Fourteen days after CVB3 infection, echocardiography, Sirius Red staining and hematoxylin-eosin (HE) were performed to describe the cardiac function and histological characteristics. Colocation of endothelial markers and mesenchymal markers were identified using confocal immunofluorescence staining. Western blot was performed to evaluate the TGF-β1/smad and Wnt/β-catenin signaling pathway. Results: A mice model of CVB3 myocarditis was made and BMP7 was administrated to CVB3-infected mice. Histological data demonstrated that BMP7 administration reduced inflammatory cells accumulation and cardiac fibrosis in response to CVB3 challenge. Echo data described cardiac dysfunction was recovered after BMP7 intervention. Double labeling of endothelial and mesenchymal markers showed BMP7-treated mice had significantly reduced the double-positive cells. Western blot described that TGF-β1/smad and Wnt/β-catenin signaling pathway was involved in this pathogenesis. Conclusions: BMP7 counteracts TGF-β1 induced endothelial-to-mesenchymal transition in viral cardiomyopathy through both TGF-β1/smad and Wnt/β-catenin signaling pathway. The research is supported by grant from the Health Joint-research Program of the National Natural Science Foundation of China and Canadian Institutes of Health Research (81010007) Background: Hypertrophic Cardiomyopathy (HCM) is a common inherited myocardial disease associated with atrial arrhythmia. Current guidelines for the management of Atrial Fibrillation (AF) do not give detailed advice on management in HCM patients because of a lack of robust clinical prediction tools that can estimate risk of developing AF and an absence of adequately powered studies. Objective: To summarise and critically review literature on AF and stroke in HCM patients and to perform a meta-analysis to determine clinical risk factors for AF and stroke. Data sources: PubMed and Web-of-Science and reference lists of related articles. Study selection: Published articles on clinical studies addressing the topic of HCM, AF and stroke in human subjects. Data extraction: 2 investigators independently extracted data from identified articles. Studies in English language investigating AF and stroke in HCM as primary or secondary endpoint were included. Reviews, case reports, abstracts were excluded. Data synthesis: A random effect meta-regression model was used to determine the pooled overall prevalence and incidence of AF and stroke. The I2 statistic was used to estimate the proportion of total variability in the data attributed to the heterogeneity between the studies. Results: In a total population of 5397 patients in 29 retrospective studies, the overall prevalence of AF was 21.61% (95% CI 19.30-23.92, I2=67.3%, p<0.01). The overall prevalence of thromboembolism in HCM patients with AF was 30.65% (95% CI 23.35-37.95, I2=85%, p<0.01). The overall incidence of AF was 2.99% (95% CI 2.48-3.50, I2=75.4% (p<0.01). The overall incidence of all thromboembolic complications in HCM patients with AF was 4.35% (95% CI 2.91-5.79, I2=62.4%, p<0.05). LA size and age were predictive for the development of AF and stroke in the majority of studies. Meta-analysis revealed an LA diameter of 38.03 mm (95% CI 34.62-41.44) in SR patients and 45.37 mm (95% CI 41.64-49.04) in AF patients. There were no randomized controlled trials of therapy; anticoagulation was associated with a lower incidence of stroke in a small number of studies, but data on the effects of pharmacological therapy and radiofrequency ablation were limited and contradictory. Conclusions: AF is common in HCM and associated with a high risk of thromboembolism. LA size and age are independently associated with AF, but the published literature is insufficient to create a robust tool for the prediction of AF or thromboembolic risk in patients in SR. There are no trials of therapy, but most data suggest that once patients have AF, they should be anticoagulated.
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Value of magnetic resonance and exercise echocardiography to predict outcome in patients with hypertrophic cardiomyopathy 
